Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome M H Cummings and G F Watts
Both hypercholesterolaemia and Oilbert's syndrome (OS) are common disorders, and it is therefore not unusual to find a patient with this liver abnormality who requires lipid-lowering therapy. The choices of lipid-lowering agent may be influenced by the knowledge that certain groups of drugs (HMO Co-A reductase inhibitors and fibrates) are contraindicated in liver disease and that nicotinic acid, a lipid-loweringagent employed in a diagnostic test for OS, stimulates a rise in plasma unconjugated bilirubin concentration.
As far as we are aware, there have been no studies examining the use of drugs for the treatment of hypercholesterolaemia in patients with OS. We therefore aimed to assess the biochemical effects of four groups of agents (bile acid sequestering agents, HMO Co-A reductase inhibitors, fibrates and acipimox) in a patient with OS to establish whether these drugs could be used safely without stimulating a significant rise in plasma bilirubin or liver enzymes.
Case Report
A 49-year-old man was screened for hyper cholesterolaemia following a myocardial infarction and triple coronary artery bypass surgery. He was found to have a fasting plasma total cholesterol (TC) concentration of 9·1 mmol/L, high-density-lipoprotein cholesterol (HDL-C) concentration of 0·9 mmol/L, triglyceride (TO) concentration of 1·4 mmol/L and a calculated low-density-lipoprotein cholesterol (LDL-C) concentration of 7· 6 mmollL. There was a family history of hypercholesterolaemia in his father and brothers, and on examination tendon xanthomata were noted, in keeping with the diagnosis of heterozygous familial hypercholesterolaemia. An incidental finding was a raised plasma bilirubin concentration (93 /Lmol/L) which was predominantly unconjugated (89/Lmol/L).
This increased bilirubin level had been noted over the previous 12 months with otherwise normal liver function tests (alanine transaminase, alkaline phosphatase, total protein, albumin and 'Y-glutamyltransferase). There was no past history of hepatitis, excess alcohol intake or ingestion of drugs likely to affect liver function. Subsequent investigations revealed the bilirubin concentration to rise during a 48 h fast (400 calories/day, unconjugated bilirubin increased from 33 to 93 /LmoIlL). There was no bilirubin or excess of urobilinogen in the urine. The reticulocyte count and 51Cr-Iabelled red blood survival tests were normal. Hepatic ultrasound showed no structural abnormality. Hence, the patient fulfilled the criteria for the diagnosis of OS.1
We investigated the biochemical effects of different classes of lipid lowering agents (Table 1) in this patient, the order of administration being illustrated in Fig. 1 . There was no significant rise in bilirubin level following the introduction of each lipid-lowering drug (Fig. 1 ). Liver enzymes remained normal throughout the study whilst bilirubin or an excess of urobilinogen was not detected in the urine at any stage. The patient experienced no side effects during drug treatment other than initial transient flushing with acipimox which settled spontaneously, and, in particular, did not report any jaundice. The effects of drug treatment on fasting plasma LDL-C, HDL-C and TO concentrations are shown in Fig. 2 . In view of the more pronounced decrease in LDL-C concentration with the combination of a bile acid sequestrant and HMO Co-A reductase inhibitor, he was subsequently treated with colestipol 10 g bd and simvastatin 20 mg/day. Eighteen months later his plasma TC was 5' 6 mmol/L, reported no side effects from his drug treatment and no exacerbation of GS.
DISCUSSION
Hypercholesterolaemia is a common finding. It has been estimated that in the UK 26% of men and 24070 of women have a total cholesterol concentration above 6· 5 mmol/L. 2 Similarly GS, defined as the presence of unconjugated hyperbilirubinaemia of at least 6 months duration in a patient with no clinical or laboratory evidence of liver disease or overt haernolysis;' is not an infrequent finding and affects 2-5% of the population.! It is, therefore, not unusual to be in a situation of managing a patient with hypercholesterolaemia in whom GS co-exists. Whilst GS is often asymptomatic, rises in unconjugated bilirubin may be associated with fatigue, non-specific gastrointestinal symptoms and abdominal pain.' Thus, the avoidance of factors known to exacerbate GS, including drug therapy, is an important part of management.
Our patient was treated with four classes of lipid-lowering agents; a bile acid sequestrant (contra-indicated in biliary obstruction which might have been suspected initially in our patient), a fibrate and HMG Co-A reductase inhibitors (groups of drugs that are contra-indicated in the presence of liver disease) and acipimox, a derivative of nicotinic acid. We demonstrated that colestipol, pravastatin, Bezalip Mono and acipimox had no adverse effects on this patient's plasma bilirubin concentration or hepatic function and could be used to treat hypercholesterolaemia. Whilst on simvastatin, the patient had a mildly raised bilirubin level which, however, had been noted just prior to treatment with this drug. Furthermore, during treatment with simvastatin over an 18 months period to-date, there have not been any associated clinical features of GS. It is possible that the raised bilirubin concentration observed whilst taking this drug is related to hepatic accumulation as a result of its hydrophobic properties. This is in contrast to the other lipid-lowering agents used in this study which have hydrophilic properties." The finding that acipimox was not associated with a rise in bilirubin was of particular interest since nicotinic acid administered intravenously in GS is known to cause an increase in unconjugated bilirubin concentration' and is used as a diagnostic test for this condition." These contrasting effects on bilirubin may be explained by differences in the route of administration rather than inherent biochemical differences between nicotinic acid and acipimox.
We believe that the high bilirubin concentration prior to the introduction of treatment was induced by recent physical illness. Thus, the decrease in bilirubin levels which were noted following the introduction of colestipol were in fact due to spontaneous improvement of his GS and not due to the effects of colestipol. This conclusion is substantiated by the finding that his bilirubin level decreased to 19 ILmol/L when he was off all treatment and was not physically stressed (data not shown).
We conclude that colestipol, pravastatin, bezafibrate and acipimox had no deleterious effect in our patient with GS and could be used to lower plasma LDL-C levels either alone or in combination. Although bilirubin levels were mildly raised when the patient was treated with simvastatin, there was no clinical exacerbation of his GS. Whilst certain lipid lowering agents are contra-indicated in the presence of liver disease, it appears that they can be used successfully in patients with GS.
